Skip to main content
Premium Trial:

Request an Annual Quote

ImmunoScape Raises $14M

NEW YORK — ImmunoScape, a Singapore-based developer of immune profiling technologies, said on Tuesday that it has raised $14 million in new funding.

The financing was led by Anzu Partners and included existing investor EDBI, an investment arm of the Economic Development Board of Singapore, and new investor Amgen Ventures.

ImmunoScape has developed a platform that uses proprietary combinatorial barcoding to enable the discovery and in-depth characterization of rare cancer-specific T cells at high resolution. According to the company, this allows for the simultaneous evaluation of tens of millions of T cells in blood samples from hundreds of cancer patients to identify rare, clinically relevant clones. The corresponding T-cell receptors (TCRs) are then evaluated and prioritized to build a diverse portfolio of TCR-T-cell therapies, it said.

"The new funding will allow us to expedite our development efforts and help us to advance our therapeutic candidates toward the clinic," ImmunoScape CEO Choon Peng Ng said in a statement.

About a year and a half ago, ImmunoScape raised $14 million to grow its team and help expand its presence in the US.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.